Urothelial carcinoma of the bladder comprises two long-recognized disease entities with
distinct molecular features and clinical outcome. Low-grade non-muscle-invasive tumours …

The prognosis and treatment of bladder cancer have improved little in the past 20 years.
Bladder cancer remains a debilitating and often fatal disease, and is among the most costly …

Although substantial progress has been made in cancer biology and treatment, clinical
outcomes of bladder carcinoma (BC) patients are still not satisfactory. The tumor …

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

Bladder cancer is the fifth most prevalent cancer in the US, yet is understudied, and few
laboratory models exist that reflect the biology of the human disease. Here, we describe a …

Urothelial carcinoma of the bladder is a common malignancy that causes approximately
150,000 deaths per year worldwide. So far, no molecularly targeted agents have been …

We sought to define whether there are intrinsic molecular subtypes of high-grade bladder
cancer. Consensus clustering performed on gene expression data from a meta-dataset of …

Immunotherapies targeting the PD-1/PD-L1 axis are now a mainstay in the clinical
management of multiple cancer types, however, many tumors still fail to respond. CCL2 is …

Global mRNA expression analysis is efficient for phenotypic profiling of tumours, and has
been used to define molecular subtypes for almost every major tumour type. A key limitation …

Purpose: To investigate genomic differences between urothelial carcinomas of the upper
tract (UTUC) and bladder (UCB), with a focus on defining the clonal relatedness of …